Table 3.

Differences in adjusted median treatment satisfaction subscale scores compared to methotrexate monotherapy.

	Current treatment, β (95% CI)
TSQM subscales	Topical only	Methotrexate	Cyclosporine	Acitretin	Adalimumab	Etanercept
Effectivenessa	−12.5 (−17.3 – −7.7)	[ref.]	−2.4 (−13.8 – 9.0)	−7.7 (−16.4 – 0.9)	11.3 (6.0 – 16.6)	11.3 (6.2 – 16.4)
Convenienceb	−13.5 (−17.7 – −9.3)	[ref.]	−2.6 (−12.7 – 7.4)	−5.8 (−13.3 – 1.7)	−2.4 (−7.1 – 2.3)	−1.3 (−5.8 – 3.1)
Overall Satisfactionc	−8.9 (−13.0 – −4.8)	[ref.]	7.2 (−2.6 – 17.0)	−7.2 (−14.6 – 0.2)	7.8 (3.2 – 12.3)	7.8 (3.4 – 12.1)

	Current treatment, β (95% CI)
TSQM subscales	Infliximab	Ustekinumab	NB UVB	MTX-ADA	MTX-ETA	MTX-INF
Effectivenessa	7.1 (−0.9 – 15.2)	8.9 (2.4 – 15.5)	8.3 (2.6 – 14.1)	8.9 (1.4 – 16.4)	2.4 (−8.0 – 12.8)	4.8 (−4.0 – 13.5)
Convenienceb	−11.1 (−18.2 – −4.0)	2.6 (−3.1 – 8.4)	−7.4 (−12.4 – −2.4)	−2.1 (−8.7 – 4.5)	−6.9 (−16.0 – 2.3)	−6.9 (−14.6 – 0.8)
Overall Satisfactionc	4.4 (−2.5 – 11.4)	7.8 (2.1 – 13.4)	7.2 (2.3 – 12.1)	8.3 (1.9 – 14.8)	6.1 (−2.8 – 15.0)	3.9 (−3.6 – 11.4)

TSQM, Treatment Satisfaction Questionnaire for Medication version II; NB UVB, narrowband ultraviolet B phototherapy; β, regression coefficient; CI, confidence interval; ref., reference; MTX, methotrexate; ADA, adalimumab; ETA, etanercept; INF, infliximab

Note: Regression modelling was not performed on the Side Effect subscale due to the low prevalence of dissatisfaction related to side effects.

^aAdjusted for recruitment site, duration of psoriasis diagnosis (categorised as <10, 10-19, 20-29, and ≥30 years), and frequency of topical treatment use (number of days in the past week).

^bAdjusted for recruitment site, age (categorised as 18-34, 35-44, 45-54, 55-64, and >65 years old), and frequency of topical treatment use.

^cAdjusted for recruitment site, duration category of psoriasis diagnosis, and frequency of topical treatment use.